Application of polypeptide in regulation of immunocompetence of macrophages
By using the polypeptide QSP to reduce the release of inflammatory factors in macrophages, the problem of side effects of existing drugs in treating inflammation is solved, safe and efficient anti-inflammatory effects are achieved, and potential applications for drug and cell culture development are provided.
Patent Information
- Application Number
- CN202410945008.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-22
AI Technical Summary
Existing clinical drugs have varying degrees of side effects when treating inflammation, and finding safer anti-inflammatory drugs is the focus of preventing and/or treating inflammation-related diseases.
A heptapeptide with a polypeptide (QSP) amino acid sequence of GFGFGGF is proposed, which has anti-inflammatory biological activity by reducing the weight of NO, IL-6, IL-1β, TNF-α and other inflammatory factors released by mouse macrophages induced by LPS. And it is low in cytotoxicity and is used to prevent and/or treat inflammatory diseases or inhibit the inflammatory response of macrophages.
It effectively reduces the release of inflammatory factors in LPS-induced macrophages, shows strong anti-inflammatory effects, and has potential value for drug and cell culture development due to its low cytotoxicity and high safety.
Smart Images

Figure BDA0004945374260000041 
Figure HDA0004945374300000011 
Figure HDA0004945374300000012
Abstract
Description
Technical Field
[0001] The invention belongs to the field of bioengineering technology, and specifically relates to an application of a polypeptide in regulating the immune activity of macrophages. Background Art
[0002] Inflammation is a natural protective response to microbial infection and tissue damage, and its function is to eliminate harmful stimuli and repair damaged tissues. Generally speaking, inflammation is beneficial and is an automatic defense response of the human body. However, disordered inflammation can become harmful and healthy cells can be damaged. As a result, further inflammatory responses are activated, which can lead to organ failure and sepsis. Mediators involved in inflammatory responses such as NO, inflammatory cytokines, PEG2, etc. are released in large quantities, thereby affecting the occurrence and development of the disease. Although existing clinical drugs can treat various types of inflammation, they all have side effects to varying degrees. Therefore, finding anti-inflammatory drugs with higher safety is the current focus of preventing and / or treating inflammation-related diseases. Summary of the invention
[0003] The present invention aims to solve at least one of the technical problems in the above-mentioned technology to a certain extent. To this end, the present invention proposes the use of a polypeptide in regulating the immune activity of macrophages, which has anti-inflammatory biological activity, low cytotoxicity and good safety, and can be used to prevent and / or treat inflammatory diseases or to inhibit LPS-induced inflammatory response of macrophages.
[0004] The present invention is based on the inventor's discovery and understanding of the following facts and problems:
[0005] First, the inventors conducted a composite enzymatic hydrolysis on the skin of Rana spinosa in the study of separation and purification of food-derived polypeptides, and discovered a heptapeptide (QSP) with an amino acid sequence of GFGFGGF through relevant in vitro enzyme activity experiments. Further experimental verification showed that QSP can reduce the amount of NO released by LPS-induced mouse macrophages RAW 264.7, inhibit the amount of inflammatory factors (IL-6, IL-1β, TNF-α) released by LPS-induced mouse macrophages RAW 264.7, and has low cytotoxicity and good safety, and can be used to prevent and / or treat inflammatory diseases or to inhibit the inflammatory response of LPS-induced macrophages.
[0006] Therefore, in the first aspect of the present invention, a non-therapeutic application of a polypeptide in macrophage immunomodulatory activity is provided, wherein the amino acid sequence of the polypeptide is shown in SEQ ID NO: 1.
[0007] GFGFGGF (SEQ ID NO: 1).
[0008] According to the application of the present invention, the polypeptide can reduce the amount of NO released by LPS-induced mouse macrophages RAW 264.7, inhibit the amount of inflammatory factors (IL-6, IL-1β, TNF-α) released by LPS-induced macrophages, has anti-inflammatory biological activity, low cytotoxicity and good safety, and can be used for non-therapeutic applications in macrophage immunoregulatory activity.
[0009] In a second aspect of the present invention, provided is the use of a polypeptide or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and / or treating inflammatory diseases, wherein the amino acid sequence of the polypeptide is shown in SEQ ID NO: 1.
[0010] According to the application of the present invention, the polypeptide can reduce the amount of NO released by LPS-induced mouse macrophage RAW 264.7, inhibit the amount of inflammatory factors (IL-6, IL-1β, TNF-α) released by LPS-induced macrophages, has anti-inflammatory biological activity, low cytotoxicity and good safety, and can be used to prevent and / or treat inflammatory diseases. Therefore, the polypeptide of the present invention can be further used in the development of products such as drugs and cell cultures.
[0011] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 The figure is a result diagram of the effect of different concentrations of QSP on the growth and proliferation of RAW 264.7 macrophages according to an embodiment of the present invention, and different letters indicate that the average values have significant differences (P<0.05);
[0013] Figure 2 is a standard curve of NO release according to an embodiment of the present invention;
[0014] Figure 3 This is a result diagram showing the effect of different concentrations of QSP on the amount of NO released by RAW 264.7 macrophages induced by LPS according to an embodiment of the present invention, and different letters indicate that the average values have significant differences (P<0.05);
[0015] Figure 4 This is a result diagram showing the effect of different concentrations of QSP on the amount of inflammatory cytokine IL-6 released by RAW 264.7 macrophages induced by LPS according to an embodiment of the present invention, and different letters indicate that the average values have significant differences (P<0.05);
[0016] Figure 5This is a graph showing the effect of different concentrations of QSP on the amount of inflammatory cytokine IL-1β released by RAW 264.7 macrophages induced by LPS according to an embodiment of the present invention, and different letters indicate that the average values have significant differences (P<0.05);
[0017] Figure 6 This is a graph showing the effect of different concentrations of QSP on the amount of inflammatory cytokine TNF-α released by RAW 264.7 macrophages induced by LPS according to an embodiment of the present invention. Different letters indicate that the average values have significant differences (P<0.05). DETAILED DESCRIPTION
[0018] Embodiments of the present invention are described in detail below, examples of which are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limiting the present invention.
[0019] The disclosure below provides many different embodiments or examples to realize different implementations of the present invention. In order to simplify the disclosure of the present invention, specific embodiments or examples are described below. Of course, they are only examples, and the purpose is not to limit the present invention. In addition, the examples of various specific processes and materials provided by the present invention, those of ordinary skill in the art can be aware of the applicability of other processes and / or the use of other materials. Unless otherwise stated, the implementation of the present invention will adopt the traditional techniques in the fields of chemistry, molecular biology, etc. within the capabilities of those skilled in the art. In addition, unless otherwise stated, in this article, nucleic acids are written from left to right in the direction of 5' to 3', and amino acid sequences are written from left to right in the direction of amino terminal to carboxyl terminal.
[0020] Terms and Definitions
[0021] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. The abbreviations for amino acid residues are standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids.
[0022] Peptides:
[0023] The present invention provides a polypeptide, or a pharmaceutically acceptable salt thereof. According to an embodiment of the present invention, the amino acid sequence of the polypeptide is shown in SEQ ID NO:1.
[0024] Amino acid sequence: GFGFGGF (SEQ ID NO: 1).
[0025] It should be noted that, in this article, "polypeptide" is sometimes also referred to as "QSP" or "heptapeptide" or "bioactive peptide" or "bioactive polypeptide".
[0026] The QSP according to the present invention can reduce the amount of NO released by LPS-induced macrophages, inhibit the amount of inflammatory factors (IL-6, IL-1β, TNF-α) released by LPS-induced macrophages, has anti-inflammatory biological activity, low cytotoxicity and good safety, and can be used to prevent and / or treat inflammatory diseases or to inhibit the inflammatory response of LPS-induced macrophages. Therefore, the pharmaceutical composition prepared by using the polypeptide of the present invention or its pharmaceutically acceptable salt has anti-inflammatory biological activity and can be further used in the development of products such as drugs and cell cultures.
[0027] The present invention is described below by means of illustrative specific examples, which are not intended to limit the scope of the present invention in any way. It is particularly noted that the reagents used in the present invention are commercially available unless otherwise specified.
[0028] Example 1 Effects of different concentrations of polypeptide QSP on the growth and proliferation of RAW 264.7 macrophages
[0029] The amino acid sequence of the polypeptide is shown in SEQ ID NO: 1, and the molecular weight is 687.3016.
[0030] Cell culture and passaging: Mouse macrophage RAW 264.7 was cultured in a cell culture incubator at 37°C and 5% CO2. The cells were cultured in a 6 cm culture dish containing 4 mL complete medium (DMEM) containing 10% FBS and 1% PS. When passaging, pour out the liquid in the culture dish and wash once with 2 mL PBS buffer. Add 2 mL of complete medium to the culture dish, use a pipette to gently tilt and blow about 20 times. The blowing can be divided into areas in a nine-square grid. The cells are passaged to a new culture dish at a ratio of 1:3-1:5. The passaged cells are marked and placed in the incubator for further culture.
[0031] Cell plating and peptide intervention: RAW 264.7 macrophages in the logarithmic growth phase were counted and the number of cells was calculated as 5×10 4 / well was inoculated into a 96-well plate and cultured in a 37°C constant temperature incubator (containing 5% CO2) until the cells adhered to the wall. The 10 mg / mL polypeptide stock solution (the polypeptide stock solution was dissolved in complete culture medium) was gradiently diluted with complete culture medium to a concentration of 10 μg / mL, 100 μg / mL, 250 μg / mL, 500 μg / mL, and 1000 μg / mL of polypeptide dilution solution. The 96-well plate was removed, the old culture medium was discarded, and 100 μL of polypeptide dilution solutions of different concentrations were added (different concentrations of polypeptide intervention groups, each polypeptide dilution concentration was set to 6 replicates) and incubated for 24 hours. Subsequently, the old culture medium was discarded, 100 μL of 0.75 mg / mL MTT solution was added to each well and incubated for another 4 hours, and the absorbance value was measured at 490 nm. The complete culture medium without polypeptide solution was used as the blank control, and the cell survival rate was calculated according to formula (1): Where: A1 is the absorbance value of the sample group, and A2 is the absorbance value of the blank group.
[0032]
[0033] The results are as follows Figure 1 As shown. When the concentration of the polypeptide solution was 10μg / mL, 100μg / mL, 250μg / mL, 500μg / mL, and 1000μg / mL, the survival rate of RAW264.7 macrophages was not significant compared with the blank group, and the survival rate was above 100%, indicating that the polypeptide of the present application had no significant effect on the survival rate of RAW264.7 macrophages (P<0.05), and could promote cell proliferation to a certain extent at concentrations of 1000μg / mL and below. Therefore, the subsequent experiments of this application selected 250, 500, and 1000μg / mL as the low, medium, and high dose groups of the polypeptide group for the next step of verification.
[0034] Example 2 Effects of different concentrations of peptide QSP on LPS-induced NO production in RAW264.7 macrophages
[0035] RAW264.7 macrophages in the logarithmic growth phase were taken for cell counting, and 3×10 5 / well was inoculated into a 12-well plate and cultured in a 37°C constant temperature incubator (containing 5% CO2) until the cells adhered to the wall. The polypeptide mother solution was diluted with complete culture medium, and 100 μL of the above dilution was added to each well for incubation for 12 hours, and then LPS was added to an LPS concentration of 1 μg / mL and continued to incubate for 12 hours. The Griess method was used to determine the NO release in the cell culture medium, that is, 50 μL of supernatant was mixed with 50 μL of Griess reagent A (1% sulfonamide) and Griess reagent B (0.1% N-1-naphthylethylenediamine hydrochloride), the OD value was detected at 540 nm, and the sample NO concentration was calculated according to the standard curve.
[0036] NO release detection standard curve: Using the Griess method, using NaNO2 standard dilution as a control, draw a standard curve for NO content detection, the ordinate is the absorbance value, the abscissa is the concentration of NaNO2, the experimental results are as follows Figure 2 As shown, the standard curve equation is Y = 0.0058x + 0.0541, R 2 =0.9999, indicating a good linear relationship, which can be used to calculate and compare NO content.
[0037] The experimental results are as follows Figure 3 As shown: Compared with the blank group (N), the NO release of the model group (M) induced by LPS was significantly increased, indicating that LPS can significantly promote the production of inflammatory mediator NO, and the cellular inflammation model was successfully established. Compared with the model group, the NO release of the peptide group added with peptide diluent was significantly reduced (P<0.05), and was dose-dependent in the range of 250-1000μg / mL. When the concentration of the peptide solution was 1000μg / mL, the NO release of the sample group was the least.
[0038] The above results show that the polypeptide QSP of the present application can inhibit LPS-induced NO secretion in RAW264.7 cells and has a strong anti-inflammatory effect.
[0039] Example 3 Effects of different concentrations of polypeptide QSP on LPS-induced production of inflammatory factors in RAW264.7 macrophages
[0040] RAW264.7 macrophages in the logarithmic growth phase were taken for cell counting, and 3×10 5 / well was inoculated into a 12-well plate and cultured in a 37°C constant temperature incubator (containing 5% CO2) until the cells adhered to the wall. The polypeptide mother solution was diluted with complete culture medium, and 100 μL of the above dilution was added to each well for incubation for 12 hours, and then LPS was added to an LPS concentration of 1 μg / mL and continued to incubate for 12 hours. The cell culture medium was collected into a centrifuge tube, shaken and mixed, and centrifuged at 25°C, 1200 rpm for 10 minutes. The ELISA kit (IL-6, IL-1β, TNF-α ELISA kits were purchased from Wuhan Abotek Biotechnology Co., Ltd.) was used to detect the release of inflammatory factors in the cell culture medium. The results are as follows Figure 4-Figure 6 As shown, compared with the N group, the release of IL-6, IL-1β, and TNF-α inflammatory factors in the culture medium of the M group was significantly increased, while the release of inflammatory factors in the polypeptide group was significantly inhibited compared with the M group, and was dose-dependent. The number of inflammatory factors in the 1000 μg / mL polypeptide group was the least.
[0041] The above results show that the polypeptide QSP of the present application can inhibit the amount of inflammatory factors (IL-6, IL-1β, TNF-α) released by RAW 264.7 cells induced by LPS, showing a strong anti-inflammatory effect.
[0042] In summary, according to an embodiment of the present invention, a polypeptide with anti-inflammatory activity is provided. The polypeptide of the present application can reduce the amount of NO released by LPS-induced mouse macrophages RAW 264.7, inhibit the amount of inflammatory factors (IL-6, IL-1β, TNF-α) released by LPS-induced mouse macrophages RAW 264.7, has anti-inflammatory biological activity, and has low cytotoxicity and good safety. It can be used to prevent and / or treat inflammation-related diseases or to inhibit the inflammatory response of LPS-induced mouse macrophages RAW 264.7. Thus, the pharmaceutical composition prepared using the polypeptide of the present invention has anti-inflammatory biological activity and can be further used in the development of products such as drugs and cell cultures.
[0043] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms should not be understood as necessarily being directed to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification.
[0044] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. Non-therapeutic application of polypeptides in macrophage immunomodulatory activity, characterized in that: The amino acid sequence of the polypeptide is shown in SEQ ID NO:
1.
2. The use according to claim 1, characterized in that The polypeptide is used for inhibiting the inflammatory response of macrophages induced by LPS.
3. The use according to claim 1 or 2, characterized in that: The polypeptide reduces the amount of NO released by LPS-induced macrophages; the polypeptide inhibits the amount of inflammatory factors released by LPS-induced macrophages.
4. The use according to claim 3, characterized in that The inflammatory factors are IL-6, IL-1β, and TNF-α.
5. Use of a polypeptide or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and / or treating inflammatory diseases, characterized in that: The amino acid sequence of the polypeptide is shown in SEQ ID NO:1.
Citation Information
Cited By
Polypeptide and application thereof in preparation of anti-inflammatory product
CN121873177A
A polypeptide and its use in the preparation of anti-inflammatory products
CN121873177B
